Intramuscular and Intravenous VIR-7831 (Sotrovimab) for Mild/Moderate COVID-19.

NCT04913675 · clinicaltrials.gov ↗
PHASE3
Phase
TERMINATED
Status
1065
Enrollment
INDUSTRY
Sponsor class

Stopped The safety sub-study was discontinued early in the context of evolving variants with increased fold changes in the in vitro half maximal inhibitory concentration (IC50) and uncertainty in the clinical relevance of these changes

Conditions

Interventions

Sponsor

Vir Biotechnology, Inc.

Collaborators